Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT04892446. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Study identification
- NCT ID
- NCT04892446
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Gilead Sciences
- Industry
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Interventions
- Magrolimab Drug
- Daratumumab Drug
- Pomalidomide Drug
- Dexamethasone Drug
- Bortezomib Drug
- Carfilzomib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 8, 2021
- Primary completion
- Apr 24, 2024
- Completion
- Apr 24, 2024
- Last update posted
- May 1, 2025
2021 – 2024
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates , PC - HOPE | Tucson | Arizona | 85711 | — |
| US San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| Stanford Cancer Institute | Palo Alto | California | 94305 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Memorial Sloan Kettering Cancer Center - Main Campus | New York | New York | 10065 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| Cleveland Clinic - Taussig Cancer Institute | Cleveland | Ohio | 44195 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| Hightower Clinical | Oklahoma City | Oklahoma | 73102 | — |
| Bend Memorial Clinic, P.C. d/b/a Summit Health | Bend | Oregon | 97701 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| US Oncology, Inc. IRB | Dallas | Texas | 75246 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| US Oncology, Inc., IRB | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04892446, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 1, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04892446 live on ClinicalTrials.gov.